Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Immunotherapy
Sort By
Newest First
1 / 3
1 / 3
CDMO - Small Biotech
Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility
Julie Trulson, Ph.D.
PAO-02-24-CL-07
February 15, 2024
Tech Transfer
Transparent Communication Supports Tech Transfers Of Cis-targeted Immunotherapies
Julie Trulson, Ph.D.
PAO-02-24-CL-06
February 15, 2024
Anti-Idiotype Antibodies
Rapid Supply of Anti-Idiotype Antibodies Facilitates Preclinical and Clinical Antibody-Based Drug Development
Na Li, Ph.D.
Sino Biological
PAO-01-23-CL-01
January 13, 2023
CRISPR Research Innovation
A Cellular Engineering Breakthrough: High-Yield CRISPR Without Viral Vectors
Gladstone Institutes
PR-M08-22-05
August 25, 2022
Polyclonal Antibodies
Advancing a New Class of Immunotherapies
SAb Biotherapeutics
PAO-04-22-R250-70
April 21, 2022
Oncolytic Viruses
Coverting Viruses into Therapeutic Tools
OncoMyx Therapeutics
PAO-04-22-R250-14
April 12, 2022
Column: Technology
mRNA Technology: Is the Long Path Behind Leading to Endless Successes Ahead?
Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.; Danielle Alvarez
Pharma's Almanac
PAO-03-022-NI-02
March 23, 2022
Alzheimer's Vaccine
Araclon Biotech Advances in Its Innovative Vaccine and Diagnostic Test for Alzheimer's
Araclon Biotech
PR-M03-22-06
March 15, 2022
Immunotherapy Research
Genetically Engineered Dual Receptor T-cells: Double Trouble for Cancer Cells
Juntendo University
PR-M01-22-23
January 31, 2022
Immunotherapy
Immune Biosolutions Reports That Its Lead Immunotherapy Product IBIO123 Neutralizes 100% of the SARS-CoV-2 Variants of Concern (VOCs), Including Omicron
Immune Biosolutions
PR-M01-22-06
January 10, 2022
Immunotherapy
Novigenix Presents New Immuno-Transcriptomic Data for Prediction of Response to Immunotherapy in Metastatic Urothelial Cancer Patients
Novigenix
PR-M09-20-21
September 17, 2020
Immunotherapy
Leveraging the Native Immune Response to Fight Cancer
Asher Nathan
NeoTX
PAP-Q2-20-CL-017
July 01, 2020
In Conversation
Novel Off-The-Shelf Targeted Cell Therapies
Gary Lord; Dago Caceres; David Alvaro, Ph.D.; Sonny Hsiao, Ph.D.
Dow Chemicals
PAP-Q2-20-CL-021
July 01, 2020
Partnership
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
Gilead Sciences
PR-M05-20-NI-041
May 28, 2020
PR-M03-20-NI-036
Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
Vaccitech Ltd.
PR-M03-20-NI-036
March 23, 2020
In Conversation
NantKwest — Harnessing Natural Killer Cells to Treat Cancer
Emilie Branch; Gary Lord; Dago Caceres; Patrick Soon-Shiong, M.D.
Pharma's Almanac
PAP-Q1-20-CL-016
March 19, 2020
Immunotherapy
NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Combination Immunotherapy in Triple Negative Breast Cancer
NantKwest
PR-M12-19-NI-022
December 16, 2019
Launch
Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines
Werewolf Therapeutics
PR-M11-19-NI-024
November 20, 2019
CAR-T Immunotherapy
Cabaletta Bio Announces Presentation of Preclinical Data Showing Specific CAAR T Activity against Anti-MuSK Expressing B Cells
Cabaletta Bio
PR-M10-19-NI-024
October 15, 2019
IND Approval
ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
ActoBio Therapeutics, Inc.
PR-M09-19-NI-006
September 04, 2019
